



Requisition for MicroVE (Microbiome) and BioER (Endometrial Receptivity)

Requisitioner Details

Medical Center/Health Facility	Department	Date	
Medical Specialist	Phone number	e-mail	
Address	City	State	Country

Requested test

MicroVE

Single test price

Follow-up program price (includes 2nd and 3rd tests when alteration detected and treatment follow-up is required)

BioER

Patient Details

Name and Surname	Age	Date of birth
ID	Phone number	e-mail

Diagnosed gynecological condition (if applies)

- IVF Failure (number of previous cycles: ___)
 Miscarriage (number of previous miscarriages: ___)

Shipping this sample along with this form to Bioarray implies the acceptance of the previously provided quotation.

The Spanish Law 14/2007 of July 3 of Biomedical Research (LIRB), establishes regulation for the performance of genetic analysis with health purposes.

In accordance with Law 41/2002 on Patient Autonomy and Law 3/2018 on the Protection of Personal Data, the applicant must have the patient's consent to carry out the diagnostic tests requested and to process his/her data. In this way, and as information to be provided to the patient, we must inform you that the data collected in this form will be included in a confidential automated file, duly registered in the Spanish Data Protection Agency, in accordance with the terms established in Law 3/2018, whose ownership corresponds to Bioarray, S.L. in order to manage the diagnostic study in the form described, the patient may exercise at any time the rights of access, rectification, cancellation or opposition, recognized by the aforementioned legislation on the protection of personal data, addressing the following address: Bioarray S.L., Parque Científico de la UMH. Edificio Quorum III 03202 Elche (Alicante), email: info@bioarray.es Tel: 966682500 Fax: 966682501

Sample Details

Sample type

Endometrial Biopsy

BIOARRAY Sticker

Endometrial biopsy method: Pipette Curette Hysteroscopy | Sample size: ____ mm

Biopsy date: _____ time: _____ 1st biopsy / 2nd biopsy

Cycle type and collection date:

HRT: P+____ (e.g. P+5)¹ First P4 intake: date _____ time _____

Natural: LH+____ (e.g. P+7)² LH surge: date _____ time _____

hCG+____(e.g. hCG+7)³ hCG injection: date _____ time _____

¹ Day of the first progesterone intake is P+0.

² Day of the LH surge is LH+0.

³ Day of the hCG injection is hCG+0.

Vaginal Sample

BIOARRAY Sticker

Sampling date: _____

Have you had any antibiotics treatment in the last month?

NO

YES

If you replied YES, please fill the requested information below:

Antibiotic prescribed

Treatment lenght

End-date of treatment

Have you ever had a prior microbiome analysis using microVE?

NO

YES

If you replied YES, please fill the requested information below:

Report date

Results

Treatment prescribed

Shipping this sample along with this form to Bioarray implies the acceptance of the previously provided quotation.

The Spanish Law 14/2007 of July 3 of Biomedical Research (LIB), establishes regulation for the performance of genetic analysis with health purposes.

In accordance with Law 41/2002 on Patient Autonomy and Law 3/2018 on the Protection of Personal Data, the applicant must have the patient's consent to carry out the diagnostic tests requested and to process his/her data. In this way, and as information to be provided to the patient, we must inform you that the data collected in this form will be included in a confidential automated file, duly registered in the Spanish Data Protection Agency, in accordance with the terms established in Law 3/2018, whose ownership corresponds to Bioarray, S.L. in order to manage the diagnostic study in the form described, the patient may exercise at any time the rights of access, rectification, cancellation or opposition, recognized by the aforementioned legislation on the protection of personal data, addressing the following address: Bioarray S.L., Parque Científico de la UMH. Edificio Quorum III 03202 Elche (Alicante), email: info@bioarray.es Tel: 966682500 Fax: 966682501

Informed Consent for Microbiome Study

DESCRIPTION, PURPOSE AND BENEFITS OF THE ANALYSIS

The test which assesses the endometrial and vaginal microbiome named **MicroVE** is a molecular test which evaluates the global profile of the bacterial populations present in the endometrium and vagina. This analysis is based on bacterial DNA detection via NGS (Next Generation Sequencing); which determines the different profiles that have been seen to affect the process of implantation and successful pregnancy. **MicroVE** can be beneficial to any woman who wishes to be a mother, especially those who experience recurring implantation failure, analysing the microbiome in the uterine and vaginal cavities, including the pathogens which most commonly cause alterations in these tissues. **MicroVE** will inform of the bacterial populations present in the samples and recommend the most appropriate actions in order to re-establish the most physiologically suitable microbiome in the uterus for embryo implantation.

PROCEDURE, RISKS AND LIMITATIONS

In order to carry out the test, an endometrial biopsy sample must be taken. This is obtained when a very thin cannula is inserted through the vagina and into the uterus, where a small cylinder of tissue is absorbed. This small sample is enough to carry out the complete analysis. During this procedure you may feel some discomfort and may slightly bleed after the biopsy, but this is a common consequence with no additional risk.

In order to process the sample, the Sample requisition Form must be completed and given in. On the contrary, the analysis may be detained until this required information is provided to the laboratory.

Due to the complexity of the genetic tests and the important implications of the test results, said results must be interpreted along with other clinical data, within the general context of a medical consultation which must be directed by health professionals. The results reports will be strictly confidential.

The test results will be available in approximately 15 working days. A small percentage of samples may be variably delayed due to unpredictable causes. If this happens the delay will be notified to the corresponding clinical entity.

It is convenient if the sampling is as close as possible to embryo transfer cycle, because the endometrial and vaginal populations could fluctuate over time due to different factors (hormonal changes, hygiene habits, general health fluctuations, the immune system, sexual relationships, additional medical treatments, etc.). It is also important that the patient has not had any antibiotic treatments within the last month before the sampling procedure. If this cannot be avoided, it must be indicated on the sample requisition form. In some cases the result may not allow a diagnosis to be established, which can occur due to insufficient bacterial DNA in the sample or because the sample has been contaminated during the sampling process, pickup or transport. If this were to happen, a new sample may be requested.

DATA PRIVACY, STORAGE AND USE OF SAMPLES FOR RESEARCH

Your privacy is a priority for Bioarray. Your identity and the data regarding your personal information will be strictly confidential. Access will only be allowed for qualified personnel at Bioarray and corresponding authorities when jurisdiction laws apply and require it.

We would like to inform you that your personal data will only be used for the following purposes: (1) Complete the obligations derived from the services hired by you; (2) Check and guarantee quality in our offered services (internal audits, quality controls, external validation of the laboratory); (3) Educational purposes, however always maintaining anonymity and not allowing identification during the analysis of the data, which will be eliminated from any publications; (4) Investigation purposes, scientific publications and presentations, in which in no case will identity data of any patients be revealed; (5) Offer personalised attention to any queries and suggestions the patient may have during the process and to ensure the correct execution and resolution of the test, including the undefined conservation of your data, except of local jurisdiction laws apply and establish the contrary; y (6) Get in contact with the patient in the future in order to

The Spanish Law 14/2007 of July 3 of Biomedical Research (LIB), establishes regulation for the performance of genetic analysis with health purposes

In accordance with Law 41/2002 on Patient Autonomy and Law 3/2018 on the Protection of Personal Data, the applicant must have the patient's consent to carry out the diagnostic tests requested and to process his/her data. In this way, and as information to be provided to the patient, we must inform you that the data collected in this form will be included in a confidential automated file, duly registered in the Spanish Data Protection Agency, in accordance with the terms established in Law 3/2018, whose ownership corresponds to Bioarray, S.L, in order to manage the diagnostic study in the form described, the patient may exercise at any time the rights of access, rectification, cancellation or opposition, recognized by the aforementioned legislation on the protection of personal data, addressing the following address: Bioarray S.L., Parque Científico de la UMH. Edificio Quorum III 03202 Elche (Alicante), email: info@bioarray.es Ph: 966682500 Fax: 966682501

request an assessment of our service, carry out commercial communications as well as participate in market research and the development of new products.

Therefore, you give consent for your gynaecologist to provide us with the information regarding the personalised embryonic transfer which is associated to the result of this test, with the purpose of completing the endometrial clinical evaluation.

You declare that you understand and accept that you will not obtain, now nor in future, any economic benefit for any investigation, and that you will not be compensated for the development of any products from any of these investigations.

Bioarray reserves the right to carry out part of or the totality of the analyses which make up the test via third accredited laboratories with well recognised quality standards, or which are periodically evaluated by Bioarray. The results obtained this way will be assessed by Bioarray.

As stated by the Personal Data Protection Act, the requisitioner must provide the patient's consent form in order to carry out the requested diagnostic tests for data analysis. You may exert at all times your right of access, rectification, opposition, deletion, automated decisions, limitation and portability of data

I DECLARE, HAVING READ AND UNDERSTOOD THE DESCRIPTION ABOVE, I AM INFORMED:

My signature at the end of this document means that I comprehend and accept the information which described here and I have had the opportunity to clear all my queiries. Therefore, I give my consent to Bioarray S.L. to use these samples in the performance of the indicated test, as well as in other centers designated by it when necessary.

DATA PROTECTION

In accordance with data protection regulations, we provide you with the following treatment information: DATA PROTECTION. In accordance with data protection regulations, we provide you with the following treatment information: Responsible party: BIOARRAY, S.L. Rights that assist you: access, rectification, portability, deletion, limitation and opposition. More treatment information: <http://bioarray.es/es/> BIOARRAY S.L. is responsible for the processing of personal data of the Interested Party and informs that these data will be treated in accordance with the provisions of Regulation (EU) 2016/679 of April 27 (GDPR) and Organic Law 3/2018 of 5 December (LOPDGDD), so the following treatment information is provided: Purposes and legitimation of the treatment. By the legitimate interest of the responsible party (GDPR, Article 6.1.f): maintaining a professional relationship, sending communications, analysing data and publishing scientific and informative articles. By consent of the interested party (GDPR, article 6.1.a): sending communications, analysing data and publishing scientific and informative articles. Data retention criteria: will be kept for no longer than necessary to maintain the end of the treatment and when it is no longer necessary for this purpose, they will be eliminated with adequate security measures to guarantee the pseudonymisation of the data or the total destruction thereof. Communication of the data: the data will not be communicated to third parties, except legal obligation. I give my consent for the storage and preservation of the samples for possible use in the research on genetic disease and I authorize the transfer of the results of the clinical studies in an anonymous form for the study and pharmacological development, the sending of communications, data analysis and publication of scientific and informative articles:

Yes **No**

Patient's Signature: _____

Name: _____

Date: _____